Fortune Brands Innovations, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Fortune Brands Innovations, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $4.46B | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $4.61B | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | $4.63B | Feb 23, 2026 |
| FY2022 | Dec 31, 2022 | $1.13B | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $1.20B | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $1.26B | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $1.14B | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $1.22B | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $1.27B | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $1.23B | Feb 28, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.38B | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $1.35B | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $1.37B | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $1.19B | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $1.30B | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $1.28B | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $1.30B | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $1.11B | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $1.22B | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $1.24B | Feb 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $472.30M | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $478.90M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $513.20M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $468.50M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $495.90M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $511.20M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $504.70M | Feb 28, 2023 |
| FY2022 | Mar 31, 2021 | $448.70M | Feb 28, 2023 |
| FY2020 | Dec 31, 2020 | $607.70M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $580.60M | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $686.70M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $772.40M | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | $553.10M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $431.90M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $389.60M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $472.60M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $413.20M | Feb 25, 2019 |
| FY2017 | Dec 31, 2015 | $315.00M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $158.10M | Feb 28, 2017 |
| FY2013 | Dec 31, 2013 | $64.20M | Feb 26, 2014 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $516.10M | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $737.90M | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | $614.90M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $774.30M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $811.10M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $233.20M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $240.20M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $173.00M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $155.00M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $192.50M | Feb 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $48.20M | Feb 26, 2020 |
| FY2019 | Dec 31, 2018 | $50.30M | Feb 26, 2020 |
| FY2019 | Dec 31, 2017 | $50.70M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $53.10M | Feb 25, 2019 |
| FY2017 | Dec 31, 2015 | $48.70M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $46.10M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $50.80M | Feb 25, 2016 |
| FY2014 | Dec 31, 2012 | $41.70M | Feb 25, 2015 |
| FY2013 | Dec 31, 2011 | $35.10M | Feb 26, 2014 |
| FY2012 | Dec 31, 2010 | $33.40M | Feb 27, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.29B | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $1.24B | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | $1.17B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $1.08B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $1.09B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $848.60M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.26B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.24B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.20B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.14B | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $478.60M | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $667.80M | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | $1.06B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $566.30M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $688.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $825.70M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $637.20M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $604.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $600.30M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $650.50M | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $111.80M | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $193.30M | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | $256.50M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $246.10M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $214.20M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $150.50M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $131.80M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $150.10M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $165.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $149.30M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $6.52B | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $6.56B | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | $6.57B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $6.12B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $5.45B | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | $7.36B | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $6.29B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $5.96B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $5.51B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $5.13B | Feb 25, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $4.13B | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $4.14B | Feb 23, 2026 |
| FY2024 | Dec 30, 2023 | $4.27B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $4.03B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $4.87B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $4.58B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.86B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $3.78B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.91B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $2.77B | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.78B | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $2.43B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $2.18B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.60B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $2.36B | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $2.45B | Feb 28, 2017 |
| FY2015 | Dec 31, 2014 | $2.26B | Feb 25, 2016 |
| FY2014 | Dec 31, 2013 | $2.65B | Feb 25, 2015 |
| FY2013 | Dec 31, 2012 | $2.38B | Feb 26, 2014 |
| FY2012 | Dec 31, 2011 | $2.12B | Feb 27, 2013 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $2.01B | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $1.99B | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | $1.91B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $1.64B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $1.54B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.47B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $2.09B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $2.08B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.91B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.83B | Feb 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $3.14B | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $2.96B | Feb 23, 2026 |
| FY2024 | Dec 30, 2023 | $2.61B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $2.32B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.81B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.18B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.76B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.45B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.17B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $814.60M | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $264.00M | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $381.10M | Feb 23, 2026 |
| FY2024 | Dec 30, 2023 | $366.40M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $642.50M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $425.60M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $419.10M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $387.90M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $262.90M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $323.00M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $251.50M | Feb 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $2.54B | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | $2.67B | Feb 23, 2026 |
| FY2024 | Dec 30, 2023 | $2.67B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $2.67B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.71B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.57B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.18B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $2.33B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.51B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $1.43B | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 2 | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | 3 | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | 3 | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 2 | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | 3 | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | 3 | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 119.96M | Feb 23, 2026 |
| FY2025 | Dec 28, 2024 | 123.64M | Feb 23, 2026 |
| FY2025 | Dec 30, 2023 | 126.29M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | 128.04M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 135.06M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 138.66M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 139.56M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | 140.50M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 151.91M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 153.41M | Feb 25, 2019 |